Citizens Downgrades Astria Therapeutics (ATXS) to Market Perform

Citizens analyst Jonathan Wolleben downgraded Astria Therapeutics (NASDAQ: ATXS) from Market Outperform to Market Perform.

The analyst comments: "BioCryst is scooping up Astria’s navenibart to expand its HAE portfolio beyond daily oral Orladeyo to a potential best-in-class injectable plasma kallikrein inhibitor delivered every three or six months; we downgrade our rating on Astria from Market Outperform to Market Perform, and we view it as highly likely that the transaction will close as announced."

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $11.61 yesterday.

You May Also Be Interested In

• Jefferies Upgrades J&J Snack Foods (JJSF) to Buy
• Booking Holdings (BKNG) PT Raised to $240 at DA Davidson
• Eli Lilly (LLY) PT Raised to $1,400 at BMO Capital